Inhibitors in patients with haemophilia A

Thrombosis Research

Volumn 134, Issue , 2014, Pages S22-S26

  Kreuz, Wolfhart ^a   Escuriola Ettingshausen, Carmen ^a  

^a HZRM Haemophilia Centre Rhein Main Frankfurt   (Germany)

Author keywords

Costs; Cumulative risk of inhibitor development; Haemophilia A; Inhibitors; Previously untreated patients; Risk management

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; DRUG COMBINATION; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; RECOMBINANT FACTOR VIII SQ;

BLEEDING DISORDER; DISEASE ERADICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; HEMOPHILIA A; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INHIBITOR DEVELOPMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DRUG COMBINATION; IMMUNOLOGY;

ANIMALS; DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; QUALITY OF LIFE; VON WILLEBRAND FACTOR;

EID: 84922602489     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.10.016     Document Type: Review

References (54)

1. Kreuz W, Ettinghausen CE, Auerswald G, Martinez Saguer I, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003;88(Suppl. 9):17-20.
2. Escuriola-Ettingshausen C, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006;12(Suppl. 6):102-6.
3. Gringeri A, Mantovani LG, Scalone L,Mannucci PM. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS study group. Blood 2003;102:2358-63.
4. KreuzW, Auerswald G, Budde U, Klose HJ, Lenk H, GTH-PUP-Study-Group. Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B. A prospective multi-center study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH). In: Scharrer I, Schramm W, editors. 35th Hemophilia Symposium Hamburg 2004. Berlin: Springer; 2005. p. 34-7.
5. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-8.
6. Klukowska A, Komrska V, Jansen M, Laguna P. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia 2011;17:399-406.
7. Escuriola Ettingshausen C, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005;16(Suppl. 1):S27-31.
8. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815-25.
9. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35.
10. Gouw SC, van der BomJG, van den Berg HM, for the CANAL Study Group. Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4693-7.
11. Astermark J.Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006;12(Suppl. 3):52-60.
12. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-Americans and Latino haemophiliacs. Haemophilia 1998;4:68.
13. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α, and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe haemophilia A. J Thromb Haemost 2009;7:2006-15.
14. Lu Y, Ding Q, Dai J,Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012;107:30-6.
15. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005;130:422-7.
16. Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention. Haemophilia 2009;15(Suppl. 1):8-14.
17. Calvez T, Laurian Y, Goudemand J. Inhibitor incidence with recombinant versus plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogenous results from four published observational studies. J Thromb Haemost 2008;6:390-2.
18. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107:46-51.
19. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13:149-55.
20. Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011;17:625-9.
21. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8:1256-65.
22. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasmaderived versus recombinant factor VIII concentrates: A critical systematic review. Crit Rev Oncol Hematol 2012;81:82-92.
23. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013;368:231-9.
24. Kessler CM, Iorio A. The RODIN (Research of Determinats if INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013;19:351-4.
25. Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012;10:781-90.
26. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007;13(Suppl. 5):65-8.
27. QaduraM,Waters B, Burnett E, Chegeni R,Hough C, Othman M, et al. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia 2011;17:288-95.
28. Hu G, Guo D, Key NS, Conti-Fine B. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007;97:788-94.
29. Chaves DG, Velloso-Rodrigues C, Oliveira CA, Teixeira-Carvalho A, Santoro MM, Martins-Filho OA. A shift towards a T cell cytokine deficiency along with an antiinflammatory/ regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients. Clin Exp Immunol 2010;162:425-37.
30. Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007;109:610-2.
31. QaduraM,Waters B, Burnett E, Chegeni R, Bradshaw S, Hough C, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009;114:871-80.
32. Delignat S, Repessé Y, Navarrete AM, Mesiler Y, Gupta N, Christophe OD, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2012;18:248-54.
33. Kreuz W, Ehrenforth S, Funk M, Auerswald G, Mentzer D, Joseph-Steiner J, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995;1:24-32.
34. KreuzW, Escuriola Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Matthes B, Schneppenheim R, et al. Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success. Haematologica 2001;86(Suppl. 4):16-22.
35. Kreuz W. The role of VWF for the success of immune tolerance induction. Thromb Res 2008;122(Suppl. 2):S7-S12.
36. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand concentrates in the treatment of hemophilia A patients. Haematologica 2003;88(Suppl. 9):21-5.
37. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007;13(Suppl. 5):73-7.
38. Kurth MA, DiMichele D, Sexauer C, Sanders JM, Torres M, Zappa SC, et al. Immune tolerance therapy utilizing factor VIII/vonWillebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008;14:50-5.
39. Greninger DA, Sain-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008;14:295-302.
40. Coppola A, Arbasi MC, Biasoli C, Messina M, Tagliaferri A, Scaraggi F. Immune tolerance induction (ITI)with a FVIII concentrate with highVWF content in inhibitor patients with previous unsuccessful ITI and/or negative predictors of ITI response. Haemophilia 2010;16(Suppl. 4):1-158.
41. Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011;9:2229-34.
42. Schmidbauer S, Metzner H, Witzel R, Cuesta-Linker T, Schulte S. Von Willebrand factor content of high-purity Factor VIII concentrate Beriate® P. Kongressausgabe 52. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung e. V. 2009 in Wiesbaden. Hamostaseologie 2008;28:A93 [abstract P-19-04].
43. Brackmann HH, Gormsen J.Massive factor-VIII infusion in haemophiliac with factor- VIII inhibitor, high responder. Lancet 1977;29:933.
44. Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009;15:911-7.
45. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, the COCIS study investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006;12:154-62.
46. Woolf A, Rappaport L, Reardon P, Ciborowski J, D'Angelo E, Bessette J. School functioning and disease severity in boys with haemophilia. J Dev Behav Pediatr 1989;10:81-5.
47. Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Lenk H, Scharrer I, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499-508.
48. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96:1698-702.
49. Nilsson IM, Sundqvist SB, Ljung R, Holmberg L, Freiburghaus C, Björlin G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Scand J Haematol 1983;30:458-64.
50. Van Leeuwen EF,Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsoedin-Visser EJ, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or lowdose. Br J Haematol 1986;64:291-7.
51. BrackmannHH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn Protocol'. Vox Sang 1996;70(Suppl. I):30-5.
52. DiMichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009;15:320-8.
53. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999;5:32-9.
54. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119:1335-44